04:20 PM EDT, 05/02/2025 (MT Newswires) -- TransCode Therapeutics ( RNAZ ) said Friday that it will implement a 1-for-28 reverse stock split to increase its per-share price in order to satisfy Nasdaq's minimum bid price requirement.

The planned reverse split will reduce the number of the company's outstanding shares to approximately 833,620 shares from 23.3 million shares.

The effective date of the reverse stock split has not yet been determined, the company said.